U.S. FDA Approves Juvmo (Tavapadon) For Parkinson’s Disease In Adults On Sept 25, 2026

On September 25, 2026, the U.S. FDA approved Juvmo (Tavapadon) for the treatment of Parkinson's disease in adults. This approval is a significant milestone for AbbVie (ABBV), potentially impacting its market position in the neurological treatment sector. The approval may lead to increased revenue opportunities for the company as it expands its product offerings.